Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pneumonia I: Introduction01:30

Pneumonia I: Introduction

871
Pneumonia is an acute respiratory infection that targets the lungs, specifically the alveoli. These tiny air sacs, essential for oxygen exchange, become engorged with pus and fluid, severely hindering breathing, decreasing oxygen absorption, and causing significant pain and discomfort during respiration.
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
871
Pneumonia II: Pathophysiology01:29

Pneumonia II: Pathophysiology

2.9K
The pathophysiology of pneumonia involves the following steps:
2.9K
Autoimmune Disorders01:29

Autoimmune Disorders

1.7K
Autoimmune diseases are a group of disorders in which the body's immune system mistakenly attacks its own cells, tissues, and organs. This results from an overactive immune response against substances and tissues normally present in the body. Let's delve into the concept and mechanism of autoimmune diseases from an immune system point of view, explore different causes and examples of such diseases, and discuss potential solutions.
Concept and Mechanism of Autoimmune Diseases
The immune...
1.7K
Pneumonia IV: Management01:28

Pneumonia IV: Management

810
The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
810
Pneumonia V: Nursing management and Prevention01:30

Pneumonia V: Nursing management and Prevention

3.5K
Nursing management of pneumonia involves promoting airway patency, facilitating rest and conserving energy, encouraging fluid intake, maintaining nutrition, and educating patients.
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed....
3.5K
Pneumonia III: Complications and Assessment01:30

Pneumonia III: Complications and Assessment

851
Pneumonia poses the potential for numerous complications that warrant consideration. These complications include the following:
851

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Combining Pirfenidone With Mycophenolate Mofetil for Systemic Sclerosis-Related Interstitial Lung Disease (Scleroderma Lung Study III): An Investigator-Initiated, Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial.

ACR open rheumatology·2025
Same author

Incidence rates of interstitial lung disease events among patients with rheumatoid arthritis treated with abatacept or placebo, with background methotrexate: a post hoc pooled analysis from a compendium of clinical trials.

Seminars in arthritis and rheumatism·2025
Same author

Abatacept for the treatment of myositis-associated interstitial lung disease.

Rheumatology (Oxford, England)·2025
Same author

Real-world antifibrotic treatment patterns in patients with idiopathic pulmonary fibrosis: retrospective analyses of two large healthcare administrative databases in the United States.

Therapeutic advances in respiratory disease·2024
Same author

Efficacy and Safety of Admilparant, an LPA<sub>1</sub> Antagonist, in Pulmonary Fibrosis: A Phase 2 Randomized Clinical Trial.

American journal of respiratory and critical care medicine·2024
Same author

"I Felt Like I Mattered": Caring is a key ingredient of collaborative care for chronic illness.

Chronic illness·2024
Same journal

Cell Lysis Pneumopathy in Patients with Hyperleukocytic Acute Myeloid Leukemia.

Annals of the American Thoracic Society·2026
Same journal

Morphologic evaluation in fibrotic hypersensitivity pneumonitis: the era of quantitative CT is upon us.

Annals of the American Thoracic Society·2026
Same journal

"From Guidelines to Practice: The PuSHCon Health-Coach Model for COPD and Asthma".

Annals of the American Thoracic Society·2026
Same journal

Fine particulate matter exposure and long-term lung-function trajectory in adults with cystic fibrosis.

Annals of the American Thoracic Society·2026
Same journal

Lung Health Lessons Learned Abroad Are Critical To Understanding Lung Health at Home.

Annals of the American Thoracic Society·2026
Same journal

Impact of Elexacaftor/Tezacaftor/Ivacaftor (ETI) on Airway and Aystemic Inflammation in Cystic Fibrosis: A Systematic Review.

Annals of the American Thoracic Society·2026
See all related articles

Related Experiment Video

Updated: Jan 30, 2026

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease
04:44

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Published on: June 16, 2020

20.9K

Interstitial Pneumonia with Autoimmune Features.

Bridget A Graney1, Aryeh Fischer1,2

  • 11 Division of Pulmonary Sciences and Critical Care Medicine and.

Annals of the American Thoracic Society
|January 30, 2019
PubMed
Summary
This summary is machine-generated.

Interstitial pneumonia with autoimmune features (IPAF) is a new classification for interstitial lung disease (ILD) patients with autoimmune traits. Research is ongoing to refine IPAF criteria and understand its natural history.

Keywords:
connective tissue diseasesidiopathic interstitial pneumoniasinterstitial lung diseasespulmonary fibrosis

More Related Videos

Experimental Model to Evaluate Resolution of Pneumonia
09:49

Experimental Model to Evaluate Resolution of Pneumonia

Published on: February 17, 2023

1.9K
A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii
09:17

A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii

Published on: January 2, 2017

15.2K

Related Experiment Videos

Last Updated: Jan 30, 2026

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease
04:44

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Published on: June 16, 2020

20.9K
Experimental Model to Evaluate Resolution of Pneumonia
09:49

Experimental Model to Evaluate Resolution of Pneumonia

Published on: February 17, 2023

1.9K
A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii
09:17

A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii

Published on: January 2, 2017

15.2K

Area of Science:

  • Pulmonology
  • Rheumatology
  • Immunology

Background:

  • Interstitial lung disease (ILD) classification challenges.
  • Need for a distinct category for ILD with autoimmune features.
  • European Respiratory Society/American Thoracic Society Task Force initiative.

Purpose of the Study:

  • Introduce and define Interstitial pneumonia with autoimmune features (IPAF).
  • Summarize current understanding and research on IPAF.
  • Highlight the importance of standardized criteria for IPAF research.

Main Methods:

  • Literature review of IPAF criteria and cohort studies.
  • Analysis of retrospective patient data fulfilling IPAF criteria.
  • Inclusion of IPAF patients in clinical trials (e.g., pirfenidone treatment trial).

Main Results:

  • Substantial global interest and retrospective cohort studies on IPAF.
  • Proposed IPAF criteria facilitate uniform patient identification.
  • IPAF designation aids in studying a specific ILD phenotype.

Conclusions:

  • IPAF is a crucial first step in understanding ILD with autoimmune features.
  • Further prospective, multicenter studies are needed.
  • Refinement of IPAF criteria will improve management and treatment strategies.